IP Library › Granted Patent US 12,643,847
Granted Patent B2
US 12,643,847 · App. 18/370,574 · Granted Jun 2, 2026

Treprostinil derivatives and compositions and uses thereof

Inventors: Xiaoming Zhang (Sunnyvale, CA); Meenakshi S. Venkatraman (Fremont, CA); Cyrus K. Becker (Pleasanton, CA)
Assignee: Corsair Pharma, Inc.
C07C69/734A61K9/7023C07C53/136C07C59/11C07C59/13C07C69/28C07C69/675C07C69/68C07C69/708C07C69/712C07C69/74C07C69/75C07C69/96C07D305/08C07D307/24C07D307/30C07D309/08C07C2601/02C07C2601/04C07C2601/08C07C2601/14C07C2603/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,643,847
App. No.
18/370,574
Granted
Jun 2, 2026
Kind
B2
Abstract

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

Claims (17)

1 . A method of promoting vasodilation, inhibiting platelet activation or aggregation, inhibiting thrombus formation, stimulating thrombolysis, inhibiting atherogenesis, inhibiting cell proliferation, promoting endothelial cell membrane remodeling, reducing inflammation, or providing cytoprotection, comprising administering to a subject in need of treatment a therapeutically effective amount of a compound selected from the group consisting of:

or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, polymorph or stereoisomer thereof.

2 . The method of claim 1 , wherein the compound is administered orally.

3 . The method of claim 1 , wherein the compound is administered parenterally.

4 . The method of claim 3 , wherein the compound is administered intravenously or subcutaneously.

5 . The method of claim 1 , wherein the compound is administered topically.

6 . The method of claim 5 , wherein the compound is administered transdermally or pulmonarily by inhalation.

7 . A method of treating pulmonary arterial hypertension, comprising administering to a subject in need of treatment a therapeutically effective amount of a treprostinil derivative selected from the group consisting of:

or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, polymorph or stereoisomer thereof, in combination with an endothelin receptor antagonist or/and a phosphodiesterase type 5 (PDE5) inhibitor.

8 . The method of claim 7 , wherein the endothelin receptor antagonist is an antagonist of ET A or an antagonist of both ET A and ET B .

9 . The method of claim 7 , wherein the endothelin receptor antagonist is ambrisentan, bosentan or Actelion-1.

10 . The method of claim 7 , wherein the PDE5 inhibitor is sildenafil or tadalafil.

11 . The method of claim 7 , wherein the treprostinil derivative is administered orally.

12 . The method of claim 7 , wherein the treprostinil derivative is administered parenterally.

13 . The method of claim 12 , wherein the treprostinil derivative is administered intravenously or subcutaneously.

14 . The method of claim 7 , wherein the treprostinil derivative is administered topically.

15 . The method of claim 14 , wherein the treprostinil derivative is administered transdermally or pulmonarily by inhalation.

Continuity (8)
Continuation 17207975 · Mar 22, 2021
Continuation 16880146 · May 21, 2020
Continuation 16270965 · Feb 8, 2019
Continuation 15735546
Continuation In Part 14829180 · Aug 18, 2015
Continuation In Part 14742579 · Jun 17, 2015
Continuation In Part 14742544 · Jun 17, 2015
Related Publication 20240116847A1 · Apr 11, 2024
References Cited (379)
US 3598122A · Zaffaroni · 1971 [cited by applicant]
US 4144317A · Higuchi et al. · 1979 [cited by applicant]
US 4201211A · Chandrasekaran et al. · 1980 [cited by applicant]
US 4262003A · Urquhart et al. · 1981 [cited by applicant]
US 4306075A · Aristoff · 1981 [cited by applicant]
US 4306076A · Nelson · 1981 [cited by applicant]
US 4338457A · Aristoff · 1982 [cited by applicant]
US 4349689A · Aristoff · 1982 [cited by applicant]
US 4379454A · Campbell et al. · 1983 [cited by applicant]
US 4420632A · Aristoff · 1983 [cited by applicant]
US 4525586A · Aristoff · 1985 [cited by applicant]
US 4668814A · Aristoff · 1987 [cited by applicant]
US 4683330A · Aristoff · 1987 [cited by applicant]
US 5028628A · Tadepalli et al. · 1991 [cited by applicant]
US 5071657A · Oloff et al. · 1991 [cited by applicant]
US 5088977A · Sibalis · 1992 [cited by applicant]
US 5153222A · Tadepalli et al. · 1992 [cited by applicant]
US 5328453A · Sibalis · 1994 [cited by applicant]
US 5797898A · Santini, Jr. et al. · 1998 [cited by applicant]
US 5853751A · Masiz · 1998 [cited by applicant]
US 5972974A · Keenan · 1999 [cited by applicant]
US 6242482B1 · Shorr et al. · 2001 [cited by applicant]
US 6264990B1 · Knepp et al. · 2001 [cited by applicant]
US 6635274B1 · Masiz et al. · 2003 [cited by applicant]
US 6638528B1 · Kanios · 2003 [cited by applicant]
US 6700025B2 · Moriarty et al. · 2004 [cited by applicant]
US 6809223B2 · Moriarty et al. · 2004 [cited by applicant]
US 7199157B2 · Wade et al. · 2007 [cited by applicant]
US 7375139B2 · Aldred · 2008 [cited by applicant]
US 7384978B2 · Phares et al. · 2008 [cited by applicant]
US 7417070B2 · Phares et al. · 2008 [cited by applicant]
US 7537590B2 · Santini, Jr. et al. · 2009 [cited by applicant]
US 7544713B2 · Phares et al. · 2009 [cited by applicant]
US 8232316B2 · Phares et al. · 2012 [cited by applicant]
US 8242305B2 · Batra et al. · 2012 [cited by applicant]
US 8252839B2 · Phares et al. · 2012 [cited by applicant]
US 8349892B2 · Phares · 2013 [cited by applicant]
US 8410169B2 · Phares et al. · 2013 [cited by applicant]
US 8435944B2 · Dipietro et al. · 2013 [cited by applicant]
US 8481782B2 · Batra et al. · 2013 [cited by applicant]
US 8497393B2 · Batra et al. · 2013 [cited by applicant]
US 8519178B2 · Hogan et al. · 2013 [cited by applicant]
US 8524939B2 · Wei et al. · 2013 [cited by applicant]
US 8536363B2 · Phares et al. · 2013 [cited by applicant]
US 8563614B2 · Wade et al. · 2013 [cited by applicant]
US 8591941B2 · Kanios et al. · 2013 [cited by applicant]
US 8609134B2 · Yoneto et al. · 2013 [cited by applicant]
US 8617591B2 · Schacht et al. · 2013 [cited by applicant]
US 8658837B2 · Wei et al. · 2014 [cited by applicant]
US 8747897B2 · Kidane et al. · 2014 [cited by applicant]
US 8748657B2 · Batra et al. · 2014 [cited by applicant]
US 8765813B2 · Wade et al. · 2014 [cited by applicant]
US 8809334B2 · Clozel · 2014 [cited by applicant]
US 8846021B2 · Charles · 2014 [cited by applicant]
US 8877710B2 · Johansson et al. · 2014 [cited by applicant]
US 8940930B2 · Batra et al. · 2015 [cited by applicant]
US 8957240B2 · Hogan et al. · 2015 [cited by applicant]
US 9050311B2 · Phares et al. · 2015 [cited by applicant]
US 9102660B2 · Batra et al. · 2015 [cited by applicant]
US 9156786B2 · Batra et al. · 2015 [cited by applicant]
US 9199908B2 · Phares et al. · 2015 [cited by applicant]
US 9255064B2 · Malinin et al. · 2016 [cited by applicant]
US 9278901B2 · Phares et al. · 2016 [cited by applicant]
US 9278903B2 · Tang et al. · 2016 [cited by applicant]
US 9346738B2 · Jain et al. · 2016 [cited by applicant]
US 9371264B2 · Becker et al. · 2016 [cited by applicant]
US 9394227B1 · Zhang et al. · 2016 [cited by applicant]
US 9422223B2 · Phares et al. · 2016 [cited by applicant]
US 9469600B2 · Malinin et al. · 2016 [cited by applicant]
US 9505704B2 · Gao et al. · 2016 [cited by applicant]
US 9505737B2 · Becker et al. · 2016 [cited by applicant]
US 9643911B2 · Zhang et al. · 2017 [cited by applicant]
US 9701616B2 · Zhang et al. · 2017 [cited by applicant]
US 9776982B2 · Becker et al. · 2017 [cited by applicant]
US 9845305B2 · Becker et al. · 2017 [cited by applicant]
US 9957220B2 · Zhang et al. · 2018 [cited by applicant]
US 10053414B2 · Zhang et al. · 2018 [cited by applicant]
US 10246403B2 · Zhang et al. · 2019 [cited by applicant]
US 10344012B2 · Becker et al. · 2019 [cited by applicant]
US 10450290B2 · Becker et al. · 2019 [cited by applicant]
US 10464877B2 · Zhang et al. · 2019 [cited by applicant]
US 10464878B2 · Zhang et al. · 2019 [cited by applicant]
US 10703706B2 · Zhang et al. · 2020 [cited by applicant]
US 10752605B2 · Becker et al. · 2020 [cited by applicant]
US 10759733B2 · Zhang et al. · 2020 [cited by applicant]
US 10988435B2 · Zhang et al. · 2021 [cited by applicant]
US 11034645B2 · Zhang et al. · 2021 [cited by applicant]
US 11046666B2 · Becker et al. · 2021 [cited by applicant]
US 11407707B2 · Zhang · 2022 [cited by examiner]
US 11802105B2 · Zhang · 2023 [cited by examiner]
US 20020099034A1 · Moriarty et al. · 2002 [cited by applicant]
US 20030108512A1 · Shorr et al. · 2003 [cited by applicant]
US 20040176645A1 · Moriarty et al. · 2004 [cited by applicant]
US 20050080140A1 · Hatae et al. · 2005 [cited by applicant]
US 20050085540A1 · Phares et al. · 2005 [cited by applicant]
US 20050165110A1 · Wade et al. · 2005 [cited by applicant]
US 20050165111A1 · Wade et al. · 2005 [cited by applicant]
US 20050282901A1 · Phares et al. · 2005 [cited by applicant]
US 20070078095A1 · Phares et al. · 2007 [cited by applicant]
US 20070078182A1 · Phares et al. · 2007 [cited by applicant]
US 20070082948A1 · Phares et al. · 2007 [cited by applicant]
US 20070254032A1 · Kidane et al. · 2007 [cited by applicant]
US 20070269379A1 · Mitragotri et al. · 2007 [cited by applicant]
US 20080200449A1 · Olschewski et al. · 2008 [cited by applicant]
US 20080249167A1 · Phares et al. · 2008 [cited by applicant]
US 20080280986A1 · Wade et al. · 2008 [cited by applicant]
US 20090036465A1 · Roscigno et al. · 2009 [cited by applicant]
US 20090163738A1 · Batra et al. · 2009 [cited by applicant]
US 20100076083A1 · Olschewski et al. · 2010 [cited by applicant]
US 20100166700A1 · Charles · 2010 [cited by applicant]
US 20100282622A1 · Phares · 2010 [cited by applicant]
US 20100324313A1 · Hogan et al. · 2010 [cited by applicant]
US 20110092599A1 · Wade et al. · 2011 [cited by applicant]
US 20110118213A1 · Phares et al. · 2011 [cited by applicant]
US 20110136818A1 · Clozel · 2011 [cited by applicant]
US 20110264028A1 · Ramdas et al. · 2011 [cited by applicant]
US 20110268732A1 · Johansson · 2011 [cited by applicant]
US 20110294815A1 · Harbeson · 2011 [cited by applicant]
US 20110319641A1 · Batra et al. · 2011 [cited by applicant]
US 20120010159A1 · Rothblatt et al. · 2012 [cited by applicant]
US 20120129941A1 · Wade et al. · 2012 [cited by applicant]
US 20120184622A1 · Freissmuth et al. · 2012 [cited by applicant]
US 20120190888A1 · Batra et al. · 2012 [cited by applicant]
US 20120197041A1 · Batra et al. · 2012 [cited by applicant]
US 20120216801A1 · Olschewski et al. · 2012 [cited by applicant]
US 20120283470A1 · Batra et al. · 2012 [cited by applicant]
US 20120295980A1 · Phares et al. · 2012 [cited by applicant]
US 20130040898A1 · Johansson · 2013 [cited by applicant]
US 20130053581A1 · Wei et al. · 2013 [cited by applicant]
US 20130096200A1 · Wade et al. · 2013 [cited by applicant]
US 20130165389A1 · Schellenberger et al. · 2013 [cited by applicant]
US 20130184295A1 · Sprague et al. · 2013 [cited by applicant]
US 20130261187A1 · Phares et al. · 2013 [cited by applicant]
US 20130267734A1 · Batra et al. · 2013 [cited by applicant]
US 20130274261A1 · Sands · 2013 [cited by applicant]
US 20130289304A1 · Batra et al. · 2013 [cited by applicant]
US 20130317245A1 · Wei et al. · 2013 [cited by applicant]
US 20130317249A1 · Hogan et al. · 2013 [cited by applicant]
US 20130331593A1 · Mcgowan et al. · 2013 [cited by applicant]
US 20130337534A1 · Charles · 2013 [cited by applicant]
US 20130344038A1 · Freissmuth et al. · 2013 [cited by applicant]
US 20140018430A1 · Freissmuth et al. · 2014 [cited by applicant]
US 20140018431A1 · Wade et al. · 2014 [cited by applicant]
US 20140024856A1 · Giust et al. · 2014 [cited by applicant]
US 20140044797A1 · Johansson et al. · 2014 [cited by applicant]
US 20140193379A1 · Jeffs et al. · 2014 [cited by applicant]
US 20140249093A1 · Vetter et al. · 2014 [cited by applicant]
US 20140256730A1 · Becker et al. · 2014 [cited by applicant]
US 20140275616A1 · Batra et al. · 2014 [cited by applicant]
US 20140288314A1 · Batra et al. · 2014 [cited by applicant]
US 20140296150A1 · Hersel et al. · 2014 [cited by applicant]
US 20140303245A1 · Sprogoe et al. · 2014 [cited by applicant]
US 20140303252A1 · Kidane et al. · 2014 [cited by applicant]
US 20140322207A1 · Johansson et al. · 2014 [cited by applicant]
US 20140323567A1 · Laing · 2014 [cited by applicant]
US 20140329824A1 · Clozel · 2014 [cited by applicant]
US 20150005374A1 · Phares et al. · 2015 [cited by applicant]
US 20150050714A1 · Charles · 2015 [cited by applicant]
US 20150057325A1 · Johansson et al. · 2015 [cited by applicant]
US 20150087688A1 · Hersel et al. · 2015 [cited by applicant]
US 20150105582A1 · Batra et al. · 2015 [cited by applicant]
US 20150126761A1 · Jain et al. · 2015 [cited by applicant]
US 20150126764A1 · Hogan et al. · 2015 [cited by applicant]
US 20150148414A1 · Malinin et al. · 2015 [cited by applicant]
US 20150166503A1 · Becker et al. · 2015 [cited by applicant]
US 20150175529A1 · Malinin et al. · 2015 [cited by applicant]
US 20150259274A1 · Phares et al. · 2015 [cited by applicant]
US 20150299091A1 · Batra et al. · 2015 [cited by applicant]
US 20150376106A1 · Batra et al. · 2015 [cited by applicant]
US 20160030371A1 · Phares et al. · 2016 [cited by applicant]
US 20160051505A1 · Phares et al. · 2016 [cited by applicant]
US 20160152548A1 · Gao et al. · 2016 [cited by applicant]
US 20160243064A1 · Trehan et al. · 2016 [cited by applicant]
US 20160256425A1 · Malinin et al. · 2016 [cited by applicant]
US 20160289158A1 · Chambournier et al. · 2016 [cited by applicant]
US 20160318844A1 · Malinin et al. · 2016 [cited by applicant]
US 20160355455A1 · Phares et al. · 2016 [cited by applicant]
US 20160368854A1 · Zhang et al. · 2016 [cited by applicant]
US 20160368855A1 · Zhang et al. · 2016 [cited by applicant]
US 20160368889A1 · Becker et al. · 2016 [cited by applicant]
US 20170081303A1 · Becker et al. · 2017 [cited by applicant]
US 20170298001A1 · Zhang et al. · 2017 [cited by applicant]
US 20180016222A1 · Zhang et al. · 2018 [cited by applicant]
US 20180086730A1 · Becker et al. · 2018 [cited by applicant]
US 20180162829A1 · Becker et al. · 2018 [cited by applicant]
US 20180170855A1 · Zhang et al. · 2018 [cited by applicant]
US 20180305293A1 · Zhang et al. · 2018 [cited by applicant]
US 20190010112A1 · Zhang et al. · 2019 [cited by applicant]
US 20190241499A1 · Zhang et al. · 2019 [cited by applicant]
US 20190292163A1 · Becker et al. · 2019 [cited by applicant]
US 20200062726A1 · Becker et al. · 2020 [cited by applicant]
US 20200071257A1 · Zhang et al. · 2020 [cited by applicant]
US 20200095186A1 · Zhang et al. · 2020 [cited by applicant]
US 20200347006A1 · Zhang et al. · 2020 [cited by applicant]
US 20200407336A1 · Becker et al. · 2020 [cited by applicant]
US 20210009501A1 · Zhang et al. · 2021 [cited by applicant]
CN 1822826A · 2006 [cited by applicant]
CN 101265226A · 2008 [cited by applicant]
CN 101903324A · 2010 [cited by applicant]
CN 103193627A · 2013 [cited by applicant]
CN 103857413A · 2014 [cited by applicant]
EP 0496548A1 · 1992 [cited by applicant]
EP 1628654A2 · 2006 [cited by applicant]
EP 2252570A1 · 2010 [cited by applicant]
EP 2427054A1 · 2012 [cited by applicant]
EP 2674413A1 · 2013 [cited by applicant]
EP 2792353A2 · 2014 [cited by applicant]
EP 2792353A3 · 2015 [cited by applicant]
EP 2841109A1 · 2015 [cited by applicant]
EP 2861554A2 · 2015 [cited by applicant]
EP 2978313A1 · 2016 [cited by applicant]
EP 3060041A2 · 2016 [cited by applicant]
EP 3068752A1 · 2016 [cited by applicant]
JP 2003523935A · 2003 [cited by applicant]
JP 2003535132A · 2003 [cited by applicant]
JP 2007501281A · 2007 [cited by applicant]
JP 2014527050A · 2014 [cited by applicant]
WO 9303696A1 · 1993 [cited by applicant]
WO 0057701A1 · 2000 [cited by applicant]
WO 0193862A1 · 2001 [cited by applicant]
WO 02053517A2 · 2002 [cited by applicant]
WO 02053517A3 · 2003 [cited by applicant]
WO 03049676A2 · 2003 [cited by applicant]
WO 03049676A3 · 2003 [cited by applicant]
WO 2005007081A2 · 2005 [cited by applicant]
WO 2005007081A3 · 2005 [cited by applicant]
WO 2005058303A1 · 2005 [cited by applicant]
WO 2005058329A1 · 2005 [cited by applicant]
WO 2007100902A2 · 2007 [cited by applicant]
WO 2007127216A2 · 2007 [cited by applicant]
WO 2007134292A2 · 2007 [cited by applicant]
WO 2007127216A3 · 2007 [cited by applicant]
WO 2007134292A3 · 2008 [cited by applicant]
WO 2008002929A2 · 2008 [cited by applicant]
WO 2008049000A2 · 2008 [cited by applicant]
WO 2008002929A3 · 2008 [cited by applicant]
WO 2008098196A1 · 2008 [cited by applicant]
WO 2007100902A3 · 2008 [cited by applicant]
WO 2008049000A3 · 2009 [cited by applicant]
WO 2009078965A1 · 2009 [cited by applicant]
WO 2009152160A1 · 2009 [cited by applicant]
WO 2009158010A1 · 2009 [cited by applicant]
WO 2010018549A2 · 2010 [cited by applicant]
WO 2010018549A3 · 2010 [cited by applicant]
WO 2010075861A2 · 2010 [cited by applicant]
WO 2010075861A3 · 2010 [cited by applicant]
WO 2010129757A1 · 2010 [cited by applicant]
WO 2011005505A2 · 2011 [cited by applicant]
WO 2011015630A1 · 2011 [cited by applicant]
WO 2011005505A3 · 2011 [cited by applicant]
WO 2011123813A2 · 2011 [cited by applicant]
WO 2011134478A2 · 2011 [cited by applicant]
WO 2011123813A3 · 2011 [cited by applicant]
WO 2011134478A3 · 2011 [cited by applicant]
WO 2011153363A1 · 2011 [cited by applicant]
WO 2012006273A1 · 2012 [cited by applicant]
WO 2012009816A1 · 2012 [cited by applicant]
WO 2012088607A1 · 2012 [cited by applicant]
WO 2012095511A1 · 2012 [cited by applicant]
WO 2012107363A1 · 2012 [cited by applicant]
WO 2012107364A1 · 2012 [cited by applicant]
WO 2012143012A1 · 2012 [cited by applicant]
WO 2013022846A2 · 2013 [cited by applicant]
WO 2013024051A1 · 2013 [cited by applicant]
WO 2013024052A1 · 2013 [cited by applicant]
WO 2013024053A1 · 2013 [cited by applicant]
WO 2013022846A3 · 2013 [cited by applicant]
WO 2013143548A1 · 2013 [cited by applicant]
WO 2013160340A1 · 2013 [cited by applicant]
WO 2013174848A2 · 2013 [cited by applicant]
WO 2014022373A1 · 2014 [cited by applicant]
WO 2013174848A3 · 2014 [cited by applicant]
WO 2014089385A2 · 2014 [cited by applicant]
WO 2014110094A1 · 2014 [cited by applicant]
WO 2014110491A1 · 2014 [cited by applicant]
WO 2014089385A3 · 2014 [cited by applicant]
WO 2014150203A1 · 2014 [cited by applicant]
WO 2014160638A1 · 2014 [cited by applicant]
WO 2014179295A1 · 2014 [cited by applicant]
WO 2014203278A2 · 2014 [cited by applicant]
WO 2014203278A3 · 2015 [cited by applicant]
WO 2015061720A2 · 2015 [cited by applicant]
WO 2015073314A1 · 2015 [cited by applicant]
WO 2015061720A3 · 2015 [cited by applicant]
WO 2015138423A1 · 2015 [cited by applicant]
WO 2015138423A9 · 2015 [cited by applicant]
WO 2016010538A1 · 2016 [cited by applicant]
WO 2016055819A1 · 2016 [cited by applicant]
WO 2016081658A1 · 2016 [cited by applicant]
WO 2016120311A1 · 2016 [cited by applicant]
WO 2016176555A1 · 2016 [cited by applicant]
WO 2016205202A1 · 2016 [cited by applicant]
WO 2018106632A1 · 2018 [cited by applicant]
Galie et al. Circulation 2008, 117, 3010-3019 (Year: 2008). [cited by examiner]
CAS Registry Entry for Registry No. 35121-78-9, which entered STN on Nov. 16, 1984, 1 page. [cited by applicant]
Cochrane J.R., et al., “A Macrolactonization Approach to the Total Synthesis of the Antimicrobial Cyclic Depsipeptide LI-F04a and Diastereoisomeric Analogues,” Beilstein Journal of Organic Chemistry, 2012, vol. 8, pp. 1… [cited by applicant]
Doh H.J., et al., “Synthesis and Evaluation of Ketorolac Ester Prodrugs for Transdermal Delivery,” Journal of Pharmaceutical Sciences, May 2003, vol. 92, No. 5, pp. 1008-1017. [cited by applicant]
European Office Action received in connection with European Application No. 16732158.7, dated Oct. 7, 2019, 5 pages. [cited by applicant]
European Office Action received in connection with European Application No. 16732158.7, dated Jan. 15, 2019, 5 pages. [cited by applicant]
European Office Action received in connection with European Application No. 16732158.7, dated Jun. 8, 2020, 6 pages. [cited by applicant]
European Office Action received in connection with European Application No. 18202494; dated Jan. 16, 2020, 12 Pages. [cited by applicant]
European Office Action received in connection with European Application No. 18202494, dated Jan. 4, 2019, 9 pages. [cited by applicant]
Extended European Search Report for European Application No. 18202494.3, mailed Jan. 4, 2019, 9 Pages. [cited by applicant]
Extended European Search Report for European Application No. 20208944.7, mailed May 12, 2021, 11 Pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 14/742,544, dated Nov. 25, 2015, 44 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 15/178,637, dated Jan. 26, 2017, 16 pages. [cited by applicant]
Final Office Action received for U.S. Appl. No. 14/829,180, dated Jul. 28, 2016, 37 pages. [cited by applicant]
Final Office Action received for U.S. Appl. No. 15/927,636, dated Mar. 27, 2019, 17 pages. [cited by applicant]
Final Office Action received for U.S. Appl. No. 16/270,965, dated Oct. 15, 2019, 18 pages. [cited by applicant]
Final Office Action received for U.S. Appl. No. 16/574,538, dated Aug. 14, 2020, 23 pages. [cited by applicant]
Final Office Action received in connection with U.S. Appl. No. 16/039,566, dated Apr. 18, 2019, 8 pages. [cited by applicant]
Findlay J.W.A., et al., “Radioimmunoassay for the Chemical Stable Prostacyclin Analog, 15AU81: a Preliminary Pharmacokinetics Study in the Dog,” Prostaglandins Leukotrienes and Essential Fatty Acids, Churchill Livingsto… [cited by applicant]
Frumkin L.R., “The Pharmacological Treatment of Pulmonary Arterial Hypertension,” Pharmacological Reviews, 2012, vol. 64, pp. 583-620. [cited by applicant]
Gannes L.Z., et al., “Natural Abundance Variations in Stable Isotopes and their Potential Uses in Animal Physiological Ecology,” Comparative biochemistry and physiology Molecular & Integrative physiology, 1998, vol. 119… [cited by applicant]
Geiger J., et al., “Targeting of the Prostacyclin Specific IP1 Receptor In Lungs with Molecular Conjugates Comprising Prostaglandin 12 Analogues,” Biomaterials, Apr. 2010, vol. 31, No. 10, pp. 2903-2911. [cited by applicant]
Handbook of Pharmaceutical Additives, Gower Publishing Co, 2007. [cited by applicant]
Handbook of Pharmaceutical Excipients, The Pharmaceutical Press and the American Pharmaceutical Association, 2005, 945 pages. [cited by applicant]
Handbook of Pharmaceutical Salts, Properties, Selection and Use, Wiley-VCH, 2011. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2016/037383, mailed Dec. 28, 2017, 12 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2014/011260, mailed May 6, 2014, 10 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/037383, mailed Nov. 23, 2016, 16 Pages. [cited by applicant]
Invitation to Pay Additional Fees With Partial International Search Report Received in Connection With International Patent Application No. PCT/US2014/046920, dated Sep. 11, 2014, 7 Pages. [cited by applicant]
Invitation to Pay Additional Fees With Partial International Search Report Received in Connection With International Patent Application No. PCT/US2016/037383, dated Sep. 16, 2016, 11 Pages. [cited by applicant]
Israel Office Action received in connection with Israeli Application No. 256260, dated Oct. 29, 2019, 8 pages. [cited by applicant]
Lee J.Y., et al., Ex Parte Appeal No. 2010/007770, decided Jan. 10, 2011, 9 Pages. [cited by applicant]
Mcswain C.S., et al, “Dose Proportionality of Treprostinil Sodium Administered by Continuous Subcutaneous and Intravenous Infusion,” The Journal of Clinical Pharmacology, 2008, vol. 48, pp. 19-25. [cited by applicant]
Non-final Office Action for co-pending U.S. Appl. No. 16/880,146, dated Aug. 6, 2020, 45 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 14/742,544, dated Aug. 6, 2015, 30 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 15/178,637, dated Aug. 10, 2016, 22 pages. [cited by applicant]
Non-final Office Action received for U.S. Appl. No. 14/829,180, dated Dec. 14, 2015, 41 pages. [cited by applicant]
Non-final Office Action received for U.S. Appl. No. 15/735,546, dated Jul. 26, 2018, 32 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 15/927,636, dated Oct. 5, 2018, 68 pages. [cited by applicant]
Non-final Office Action received for U.S. Appl. No. 16/270,965, dated May 29, 2019, 29 pages. [cited by applicant]
Non-final Office Action received for U.S. Appl. No. 16/574,538, dated Apr. 16, 2020, 49 pages. [cited by applicant]
Non-final Office Action received for U.S. Appl. No. 16/580,828, dated Feb. 6, 2020, 29 pages. [cited by applicant]
Non-final Office action received in connection with U.S. Appl. No. 15/473,434; dated Jul. 26, 2017, 56 pages. [cited by applicant]
Non-final Office action received in connection with U.S. Appl. No. 15/617,243; dated Nov. 1, 2017, 24 pages. [cited by applicant]
Non-final Office Action received in connection with U.S. Appl. No. 16/039,566, dated Nov. 1, 2018, 31 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/742,544, dated Mar. 16, 2016, 8 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/178,637, dated Mar. 29, 2017, 10 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/473,434; dated Dec. 28, 2017, 8 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/617,243, dated Apr. 25, 2018, 8 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/735,546, dated Nov. 11, 2018, 7 Pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/039,566; dated Jun. 27, 2019, 8 pages. [cited by applicant]
Office Action in KR1020187001025, mailed Jan. 22, 2024, 9 pages. [cited by applicant]
Office Action for Korean Patent Application No. 10-2024-7031999, issued Oct. 21, 2024. English translation included. [cited by applicant]
Office Action for Korean Patent Application No. 10-2024-7031999, issued May 26, 2025. English translation included. [cited by applicant]
Office Action for Japanese Patent Application No. 2023-209782, issued May 26, 2025. English translation included. [cited by applicant]
Office Action for Appeal No. 2023-021184 of Japanese Patent Application No. 2021-151659, issued Jul. 15, 2025. English translation included. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/580,828, mailed Apr. 29, 2020, 7 Pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/574,538, mailed Feb. 4, 2021, 14 pages. [cited by applicant]
Notice of Allowance received for U.S. Appl. No. 14/829,180, dated Feb. 17, 2017, 13 pages. [cited by applicant]
Notice of Allowance received for U.S. Appl. No. 15/927,636, dated Jun. 24, 2019, 8 Pages. [cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/270,965, dated Mar. 5, 2020, 12 pages. [cited by applicant]
Office Action and Search Report for related Chinese Application No. 201680045679.3, mailed May 19, 2021, 15 pages. [cited by applicant]
Office Action received in connection with counterpart Indian Application No. 201817000837, dated Feb. 26, 2020, 6 pages. [cited by applicant]
Office Action received in connection with counterpart Israeli Application No. 256260, dated Aug. 31, 2020, 9 pages. [cited by applicant]
Office Action received in connection with counterpart Japanese Application No. 2017-564668, dated Jun. 17, 2020, 14 pages. [cited by applicant]
Paudel K.S., et al., “Challenges and Opportunities in Dermal/Transdermal Delivery,” Therapeutic Delivery, Jul. 2010, vol. 1, No. 1, pp. 109-131. [cited by applicant]
Pearson A.J., et al., “Handbook of Reagents of Organic Synthesis: Activating Agents and Protecting Groups,” John Wiley & Sons, 1999, 4 pages. [cited by applicant]
Pharmaceutical Pre-formulation and Formulation, CRC Press LLC, 2004, 610 pages. [cited by applicant]
Rautio J., et al., “Prodrugs: Design and Clinical Applications,” Nature Reviews: Drug Discovery, Mar. 2008, vol. 7, pp. 255-270. [cited by applicant]
Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, 2005. [cited by applicant]
Remington: The Science and Practice of Pharmacy, The Pharmaceutical Press and the American Pharmaceutical Association, 2005. [cited by applicant]
Schanz S., et al., “Topical Treatment of Erectile Dysfunction with Prostaglandin E1 Ethyl Ester,” Journal of German Society of Dermatology, 2009, vol. 7, No. 12, pp. 1055-1059. [cited by applicant]
Shiina I., “Total Synthesis of Natural 8- and 9-Membered Lactones: Recent Advancements in Medium Sized Ring Formations,” Chemical Reviews, 2007, vol. 107, pp. 239-273. [cited by applicant]
Shorr R., et al., “Prostaglandin Compounds and Derivatives for the Treatment of Congestive Heart Failure,” Caplus, Chemical Abstracts Service, Columbus, Ohio, US, Database accession No. 2001:408054, URL: Caplus, STN, 2 … [cited by applicant]
Smith M.B., et al., “March's Advanced Organic Chemistry: Reactions, Mechanisms and Structure,” 6th Edition, A John Wiley & Sons, 2007, 4 pages. [cited by applicant]
Thayer A.N., “Form and Function,” Chemical & Engineering News, Jun. 18, 2007, vol. 85, No. 25, pp. 17-30, Retrieved from the Internet: http://cen.acs.org/articles/85/i25/Form-Function.html. [cited by applicant]
Wada E., et al., “Natural Abundance of Carbon, Nitrogen, and Hydrogen Isotope Ratios in Biogenic Substances: Present and Future,” Seikagaku, The Japanese Biological Society, 1994, vol. 66, pp. 15-29 (English portions In… [cited by applicant]
Wannian Z., et al., “Modern Drug Design”, China Medical Science and Technology Press, May 31, 2006, pp. 75-80. [cited by applicant]
Wuts P., et al., “Greene's Protective Groups in Organic Synthesis,” John Wiley and Sons, 2006, 1112 pages. [cited by applicant]
Wuts P.G.M., et al., “Greene's Protective Groups in Organic Synthesis,” 4th Edition, A John Wiley & Sons, 2007, 5 pages. [cited by applicant]
Zhang X., et al., “Treprostinil Derivatives and Compositions and Uses Thereof,” U.S. Appl. No. 14/829,180, filed Aug. 18, 2015, 76 pages. [cited by applicant]
Zhichun G., et al., “New Prostacyclin Analogue Treprostinil”, Chinese Journal of New Drugs, pp. 2585-2588, 2592. [cited by applicant]
Chinese National Intellectual Property Office. Notice of Reexamination for Chinese Application No. 201680045679.3, issued Nov. 29, 2025. [cited by applicant]
Israel Patent Office. Office Action for Israeli Patent Application No. 313291, dated Feb. 2, 2026 (with English translation). [cited by applicant]
Korean Intellectual Property Office. Decision of Refusal for Korean Patent Application No. 10-2024-7031999, dated Feb. 13, 2026 (with English translation). [cited by applicant]
European Patent Office. Office Action (Communication pursuant to Art. 94(3) EPC) for European Patent Application No. 20208944.7, dated Feb. 16, 2026. [cited by applicant]